William Chin to lead PhRMA science & regulatory affairs
This article was originally published in Scrip
Executive Summary
The Pharmaceutical Research and Manufacturers of America (PhRMA) has named Dr William Chin executive vice-president of science and regulatory affairs, effective 1 July 2013. Currently, Dr Chin is the executive dean for research at Harvard Medical School. At PhRMA, he will oversee the organization's scientific and regulatory affairs portfolio, including implementation of the Prescription Drug User Fee Act (PDUFA), clinical trials, and drug discovery and research collaboration. He will report to PhRMA president and CEO John Castellani and will also become a member of the PhRMA management committee.